MedTrace Logo

Reresveratrol Administered to Healthy Male Subjects

NCT01768507 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2016-09-15

No results posted yet for this study

Summary

Heme oxygenase 1 (HO-1) serves as a protective gene. The aim of this clinical trial is to evaluate the HO-1 stimulation of resveratrol in healthy humans.

Conditions

  • Healthy Subjects
  • Heme Oxygenase

Interventions

DIETARY_SUPPLEMENT

Resveratrol

5 g (10 capsules) as single oral dose on day 1

Sponsors & Collaborators

  • Daniel Doberer

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01768507 on ClinicalTrials.gov